ORPH Orphazyme A/S - ADR

11,392

$0.03

$0.05

(62.50%)

Today

Market Cap	$1.06M
Volume (M)	23,208.00
52-Wk High	$7.48
52-Wk Low	$0.0002

ST Data

Watchers

New Watcher Rank

Fundamentals

Pomerantz LLP Announces Notice of Pendency and Proposed Settlement For All Persons Who Purchased, or Otherwise Acquired, The American Depositary Shares of Orphazyme A/S in its September 2020 Initial Public Offering or Between September 29, 2020 and NovembPR Newswire • about 2 months ago

Share to Feed

Orphazyme to submit statutory restructuring plan to Danish courtSeekingAlpha.com: All News • over 1 year ago

--- - Danish biotech firm, Orphazyme (ORPH) said it will submit the enclosed proposal for a statutory restructuring plan to the Danish Maritime and Commercial High Court and to its...

Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSsBenzinga • over 1 year ago

--- - Orphazyme A/S ORPH has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to consider the best possible path forward for arimoclomol," commented Orphazyme Chief Executive Officer Anders Vadsholt.

Dear ORPH Stock Fans, Mark Your Calendars for March 31InvestorPlace • over 1 year ago

--- - InvestorPlace - Stock Market News, Stock Advice & Trading Tips - After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. - The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on InvestorPlace...

Orphazyme pulls European marketing application for lead candidateSeeking Alpha - Healthcare • over 1 year ago

--- - Danish biotech, Orphazyme (ORPH) announced on Tuesday that the company decided to withdraw the European Marketing Authorization Application for arimoclomol for the treatment of...

Orphazyme's restructuring proceedings begun by Danish courtSeekingAlpha.com: All News • over 1 year ago

--- - Orphazyme (ORPH) said the Danish Maritime and Commercial High Court began restructuring proceedings of the company on March 11.Earlier in March the company's board decided to file...

Orphazyme A/S (NASDAQ:ORPH) Upgraded to "Buy" by Zacks Investment ResearchTicker Report • over 1 year ago

--- - Zacks Investment Research upgraded shares of Orphazyme A/S (NASDAQ:ORPH Get Rating) from a hold rating to a buy rating in a research report released on Tuesday , Zacks.com reports. They currently have $0.75 target price on the stock. According to Zacks, Orphazyme A/S is a late-stage ...

Why Is Orphazyme (ORPH) Stock Up Today?InvestorPlace • over 1 year ago

--- - InvestorPlace - Stock Market News, Stock Advice & Trading Tips - The troubled biotech company's share price is up 40% despite plans to delist from the Nasdaq exchange and lay off 50% of its workers. - The post Why Is Orphazyme (ORPH) Stock Up Today? appeared first on InvestorPlace...

Orphazyme surges on above average volumeSeekingAlpha.com: All News • over 1 year ago

--- - Orphazyme (ORPH) ADRs have added more than 37% in early trading Thursday on above average volume as investors look past the recent operational issues of the Danish biotech that led to...

Orphazyme stock slumps 40% as it plans Nasdaq delisting, halve workforce in restructuringSeekingAlpha.com: All News • over 1 year ago

--- - Orphazyme ( ORPH -39.8%) stock plummeted after the company said it intends to delist its American Depositary Shares ((ADSs)) from Nasdaq and reduce its global workforce by ~50%.